Currently, selective progesterone receptor modulators (SPRMs) such as mifepristone, ulipristal acetate, Vilaprisan, and Telapristone Acetate, which are designed to competitively bind to the PR target site in a tissue-specific manner, have been developed; although none of them have shown success in endometrial cancer treatment, several SPRMs appear to be effective in treating recurrent breast cancer, and clinical trials are currently underway to investigate their potential [60,61]. Here, PGR is linked to breast cancer.